Methodology for protein-ligand binding studies: Application to a model for drug resistance, the HIV/FIV protease system

Proteins: Structure, Function and Genetics

Volumn 36, Issue 3, 1999, Pages 318-331

  Dominy, Brian N ^a   Brooks III, Charles L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Binding free energy; Drug resistance; FIV; HIV; Protease

Indexed keywords

INDINAVIR; LIGAND; PROTEIN; PROTEINASE;

AMINO ACID COMPOSITION; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING AFFINITY; DRUG CONFORMATION; ENERGY TRANSFER; ENZYME ACTIVE SITE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; VIRUS RESISTANCE;

ANIMALS; ASPARTIC ENDOPEPTIDASES; CATALYTIC DOMAIN; CATS; DRUG RESISTANCE, MICROBIAL; ELECTROSTATICS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; LIGANDS; MODELS, BIOLOGICAL; PROTEIN BINDING; THERMODYNAMICS;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0033567032     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0134(19990815)36:3<318::AID-PROT6>3.0.CO;2-K     Document Type: Article

References (54)

1. Itzstein M, Wu W, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-423.
2. Kaldor SW, Kalish VJ, Davies II JF, et al. Viracept: a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997;40: 3979-3985.
3. Skulnick HI, Johnson PD, Aristoff PA, et al. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyranones. J Med Chem 1997;40:1149-1164.
4. Rutenber EE, De Voss JJ, Hoffman L, et al. The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibibtor of HIV-1 protease. Bioorg Med Chem 1997;5:1311-1320.
5. Brady SF, Stauffer KJ, Lumma WC, et al. Discovery and development of the novel potent oraly active thrombin inhibitor N-(9-Hydroxy-9-fluorenecarboxy)prolyl trans-4-Aminocyclohexylmethyl Amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid support. J Med Chem 1998;41:401-406.
6. Ajay; Murcko MA. Computational methods to predict binding free energy in ligand-receptor complexes. J Med Chem 1995;38:4953-4967.
7. Lightstone FC, Zheng Y, Bruice TC. Molecular dynamics simulations of ground and transition states for the Sn2 displacement of Cl- from 1,2-dichloroethane at the active site of Xanthobacter autotrophicus haloalkane dehalogenase. J Am Chem Soc 1998;120: 5611-5621.
8. Kubinyi H. QSAR and 3D QSAR in drug design, part 2: applications and problems. Drug Design Today 1997;2:538-546.
9. Hirst JD. Nonlinear quantitative structure-activity relationship for the inhibition of dihydrofolate reductase by pyrimidines. J Med Chem 1996;39:3526-3532.
10. Selassie CD, Gan W, Kallander LS, Klein TE. Quantitative structure-activity relationships of 2,4-diamino-5-(2-X-benzyl)pyrimidines versus bacterial and avian dihydrofolate reductase. J Med Chem 1998;41:4261-4272.
11. Clare BW. The frontier orbital phase angles: novel QSAR descriptors for benzene derivatives, applied to phenylalkylamine hallucinogens. J Med Chem 1998;41, 3845-3856.
12. Altomare C, Cellamare S, Summo L, et al. Inhibition of monoamine axidase-B by condensed pyridazines and pyrimidines: effects of lipophilicity and structure-activity relationships. J Med Chem 1998;41:3812-3820.
13. Kubinyi H. QSAR and 3D QSAR in drug design, part 1: methodology. Drug Design Today 1997;2:457-467.
14. Hirst JD. Predicting ligand binding affinities. Curr Opin Drug Discovery and Development 1998;1:28-33.
15. So S, Karplus M. Evolutionary optimization in quantitative structure-activity relationship: an application of genetic neural networks. J Med Chem 1996;39:1521-1530.
16. Tawa GJ, Topol IA, Burt SK, Erickson JW. Calculation of relative binding free energies of peptidic inhibitors to HIV-1 protease and its I84V mutant. J Am Chem Soc 1998;120:8856-8863.
17. Novotny J, Bruccoleri RE, Davis M, Sharp KA. Empirical free energy calculations: a blind test and further improvements to the method. J Mol Biol 1997;268:401-411.
18. Froloff N, Windemuth A, Honig B. On the calculation of binding free energies using continuum methods: application to MHC class I protein-peptide interactions. Protein Sci 1997;6:1293-1301.
19. DeWitte RS, Shakhnovich EI. SMoG: de novo design method based on simple, fast, and accurate free energy estimates. J Am Chem Soc 1996;118:11733-11744.
20. Zhang C, Cornette JL, Delisi C. Consistency in structural energetics of protein folding and peptide recognition. Protein Sci 1997;6: 1057-1064.
21. Gilson MK, Honig B. Calculation of the total electrostatic energy of a macromolecular system: solvation energies, binding energies, and conformational analysis. Proteins: Struct Func Gen 1988;4: 7-18.
22. Hansson T, Åquist J. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. Protein Eng 1995;8:1137-1144.
23. Holloway KM, Wai JM, Halgren TA, et al. A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem 1995;38:305-317.
24. Viswanadhan VN, Reddy MR, Wlodawer A, Varney MD, Weinstein JN. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease. J Med Chem 1996;39:705-712.
25. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus MJ. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. Comp Chem 1983;4:187-217.
26. Sitkoff D, Sharp KA, Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J Phys Chem 1994;98:1978-1988.
27. Shen J, Wendoloski J. Electrostatic binding energy calculation using the finite difference solution to the linearized Poisson-Boltzmann equation: assessment of its accuracy. J Comp Chem 1996;17:350-357.
28. Wlodawer A, Gustchina A, Reshetnikova L, et al. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Bio 1995;2:480-488.
29. Kervinen J, Lubkowski J, Zdanov A, et al. Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP130 complexed with proteases from HIV-1, FIV, and EIAV. Protein Sci 1998;7:2314-2323.
30. Schnolzer M, Rackwitz H, Gustchina A, et al. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. J Virol 1996;224:268-275.
31. Lee T, Laco GS, Torbett BE, et al. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci USA 1998;95:939-944.
32. Farmerie WG, Goodenow MM, Dunn BM. Cloning, expression and kinetic characterization of the feline immunodeficiency virus proteinase. Struct Func Asp Proteinases 1991;1:511-513.
33. Bernstein FC, Koetzle TF, Williams GJB, et al. The Protein Databank: A computer based archival file for macromolecular structures. J Mol Biol 1977;112:535-542.
34. Chen Z, Li Y, Chen E, et al. Crystal structure at 1.9 angstroms resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, An orally bioavailable inhibitor of the HIV proteases. J Biol Chem 1994;269:26344-26348.
35. Kirkpatrick S, Gelatt CDJ, Vecchi MP. Optimization by simulated annealing. Science 1983;220:671-680.
36. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the Cartesian equations of motion for a system with constraints: molecular dynamics of n-alkanes. J Comp Phys 1977;52:251-292.
37. Gelin BR, Karplus M. Sidechain torsional potentials and motion of amino acids in proteins: bovine pancreatic trypsin inhibitor. Proc Natl Acad Sci USA 1975;72:2002-2006.
38. Warshel A, Levitt M. Theoretical studies of enzymic reactions: dielectric, electrostatic, and steric stabilization of the carbonium ion in the reaction of lysozyme. J Mol Biol 1976;103:227-249.
39. Solmajer T, Mehler EL. Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng 1991;4:903-910.
40. Solmajer T, Mehler EL. Electrostatic screening in molecular dynamics simulations. Protein Eng 1991;4:911-917.
41. Smart JL, Marrone TJ, McCammon JA. Conformational sampling with Poisson-Boltzmann forces and a stochastic dynamics/Monte Carlo method: application to alanine dipeptide. J Comp Chem 1997;18:1750-1759.
42. Bruccoleri RE, Karplus M. Conformational sampling using high-temperature molecular dynamics. Biopolymers 1990;29:1847-1862.
43. Brunger AT, Kuriyan J, Karplus M. Crystallographic R factor refinement by molecular dynamics. Science 1987;235:458-460.
44. Brunger AT. Crystallographic refinement by simulated annealing: application to a 2.8 Å resolution structure of aspartate aminotransferase. J Mol Biol 1988;203:803-816.
45. Brunger AT, Adams PD, Rice LM. New applications of simulated annealing in X-ray crystallography and solution NMR. Structure 1997;5:325-336.
46. Bunger AT, Krukowski A, Erickson JW. Slow-cooling protocols for Crystallographic refinement by simulated annealing. Acta Cryst 1990;46:585-593.
47. Laughton CA. A study of simulated annealing protocols for use with molecular dynamics in protein structure prediction. Protein Eng 1994;7:235-241.
48. Neria E, Fischer S, Karplus M. Simulation of activation free energies in molecular systems. J Chem Phys 1996;105, 1902-1921.
49. Warwicker J, Watson HC. Calculation of the electric potential in the active site cleft due to a-helix dipoles. J Mol Biol 1982;157:671-679.
50. Jean-Charles A, Nicholls A, Sharp K, et al. Electrostatic contributions to solvation energies: comparison of free energy perturbation and continuum calculations. J Am Chem Soc 1991;113:1454-1455.
51. Erickson JW, Burt SK. Structural mechanisms of HIV drug resistance. Annu Rev Pharmacol Toxicol 1996;36:545-571.
52. Tozser J, Gustchina A, Weber IT, Blaha I, Wondrak EM, Oroszlan S. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett 1991;279:356-360.
53. Fersht A. Enzyme structure and mechanism, 2nd ed. New York: WH Freeman; 1977.
54. Lin Y, Lin X, Heng L, Fandling S, Heinrikson RL, Thaisrivongs S, Leelamanit W, Raterman D, Shah M, Dunn BM, Tang J. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type I protease: relationship to drug resistance. Biochemistry 1995;34:1143-1152.